Testosterone and Myostatin: How TRT Suppresses GDF-8

It is not just receptors and protein synthesis. Testosterone's effect on muscle is famous for what it does to anabolic signaling — but a meaningful slice of the body composition change in TRT users comes from the other side of the equation: testosterone lowers muscle myostatin expression while raising FGF2 and IGF-1.

The cleanest single data point in the literature: hypogonadal men given 250 mg testosterone every 2 weeks for 22 weeks showed a 29% reduction in muscle myostatin expression alongside a 134% increase in FGF2. That is a structural shift in the local growth environment, not just hormonal pushing.

Last Updated May 22, 2026

Testosterone and myostatin quick stats

Hypogonadal men on 250 mg testosterone every 2 weeks for 22 weeks: 29% ± 12% drop in muscle myostatin expression (Dhindsa et al, JCEM 2019)
Same study, FGF2: +134% ± 45% increase from baseline
Same study, MRF4: 28% ± 12% suppression
Same study, plasma IGF-1: 62 → 81 ng/mL
Serum myostatin in the same study: Unchanged — the effect is intramuscular
Direction of effect: Higher testosterone → lower muscle myostatin → favorable hypertrophy environment

Key takeaways

Testosterone suppresses muscle myostatin expression at the tissue level, even when circulating myostatin levels do not change. The action is local, inside the fiber.
The 29% intramuscular myostatin drop reported in hypogonadal men on standard TRT (250 mg every 2 weeks, 22 weeks) is one of the largest non-pharmacological myostatin reductions ever documented in humans.
Testosterone simultaneously raises FGF2 (a satellite-cell activator) and IGF-1 (a major anabolic signal). The combined effect is a structurally pro-hypertrophic muscle environment.
Low testosterone (whether from age, hypogonadism, or undertraining) leaves muscle myostatin expression elevated and IGF-1 lower, biasing the system toward maintenance or loss.
This is part of why TRT works on body composition even when training volume and protein intake stay the same — it is rebalancing the local muscle environment, not just adding "anabolic effect."

The biology that links the two

Testosterone does not directly bind myostatin. The connection runs through transcription. Androgen receptor activation in muscle changes gene expression patterns across a network that includes myostatin, FGF2, MRF4, IGF-1, and several other genes governing satellite cell activity, protein synthesis, and protein breakdown.

The simplified pathway:

Testosterone enters the muscle cell and binds the androgen receptor
The receptor-testosterone complex translocates to the nucleus
It modifies transcription of dozens of genes, including suppression of myostatin
Reduced myostatin transcription means less local Smad2/3 signaling
Less Smad2/3 means reduced atrogene activation and stronger IGF-1/Akt/mTOR signaling
Satellite cells (activated by FGF2 and MRF4 changes) proliferate and fuse into existing fibers
Net muscle protein balance shifts toward synthesis

This is a different mechanism than the direct protein-synthesis stimulation testosterone is most famous for. It is restructuring the local environment to make synthesis easier and breakdown slower, by lowering the brake (myostatin) rather than only pressing the accelerator (synthesis pathway).

The Dhindsa JCEM study, in detail

The cleanest single trial. Sandeep Dhindsa and colleagues (PMC6481910 / JCEM 2019) studied 12 men aged 30-65 with hypogonadotropic hypogonadism (low testosterone with low LH and FSH) and type 2 diabetes. The protocol:

Intramuscular testosterone 250 mg every 2 weeks
Duration: 22 weeks
Pre- and post-treatment muscle biopsies and serum panels

Key results:

Marker	Change
Muscle myostatin expression	−29% ± 12% (p significant)
Muscle FGF2 expression	+134% ± 45%
Muscle MRF4 expression	−28% ± 12%
Plasma IGF-1	62 → 81 ng/mL (+31%)
Serum myostatin	No significant change

The intramuscular myostatin drop is the headline. The 134% FGF2 rise is almost equally striking and points to satellite cell activation (FGF2 is a known satellite-cell mitogen).

The serum myostatin not changing is the part that confuses casual readers. In hypogonadal men with type 2 diabetes, the muscle is doing the work locally — transcription is shifting, protein expression in the fiber is shifting — but the spillover into circulating myostatin levels is not large enough to detect in standard serum assays.

This is part of why commercial blood myostatin testing is a noisy indicator of training and hormonal status. The intramuscular biology can move meaningfully without the blood number changing. See our myostatin blood test coverage.

Where this fits in TRT outcomes

The body composition data and the molecular data agree. TRT in genuinely hypogonadal men consistently produces:

Lean mass increases of 2-5 kg over 6-12 months
Fat mass decreases of 2-4 kg
Strength gains of 10-20% on standardized testing
Improved insulin sensitivity
Better physical function and energy

The myostatin-FGF2-IGF-1 axis is one of the molecular reasons this happens. The intramuscular environment shifts from neutral or net-catabolic (high myostatin, suppressed satellite cells, low IGF-1) to net-anabolic (low myostatin, activated satellite cells, high IGF-1).

This is structurally different from short-term hormonal pushes. Six months of TRT changes the local muscle environment in a way that supports continued training adaptation, not just one wave of growth.

What this means for natural lifters

The lessons from the molecular side, even if you are not on TRT.

Optimizing natural testosterone matters more than the bro-science chatter implies. Sleep, body fat, micronutrient sufficiency, and resistance training all support testosterone production. The myostatin-suppressing effect of normal testosterone is part of the standard background that keeps training adaptation working.

Crashing testosterone through under-eating or overtraining hurts gains through the myostatin axis, not just through "low T." Diet phases that drive testosterone down below normal range often plateau or reverse training progress through this mechanism. The fix is not adding test boosters; it is fixing the underlying load.

Aging-related testosterone decline contributes to age-related myostatin elevation. As natural testosterone falls 1-2% per year after age 40, muscle myostatin expression slowly drifts up. This is one molecular reason older lifters need more frequent training and more protein to maintain the same adaptation. See our myostatin and aging and myostatin and sarcopenia articles.

Women have different biology, not none. Women have far less testosterone than men but use the available pool more efficiently for muscle. The myostatin-testosterone link is preserved at the lower hormonal levels. See myostatin in women.

TRT vs anabolic steroids vs SARMs

A clinical distinction worth making. The discussion above is about therapeutic testosterone replacement in genuinely hypogonadal men under medical supervision, with doses (typically 100-200 mg per week) that bring serum testosterone back into the upper end of normal range.

The picture changes with supraphysiological doses:

Anabolic steroid abuse pushes testosterone several-fold above the natural range and produces much larger myostatin suppression and FGF2 elevation, alongside the well-documented cardiovascular, hepatic, and endocrine harms
SARMs (selective androgen receptor modulators) like ostarine and ligandrol attempt to produce androgen receptor effects in muscle without prostate or hepatic effects; some have shown myostatin-suppressing properties similar to but smaller than testosterone
YK-11 is sometimes marketed as a "myostatin SARM" but its actual myostatin-inhibition story is weak — see our YK-11 and myostatin deep-dive

The therapeutic TRT data is the cleanest because the doses are physiological and the outcomes are tracked under medical supervision. Bodybuilding-dose steroid effects are real but come with risks well outside the scope of myostatin discussion.

For broader context on the regulatory and legal status, see are myostatin inhibitors legal.

Sleep, body fat, and the testosterone-myostatin loop

The amplifiers. Three lifestyle factors strongly affect whether the testosterone-myostatin axis functions:

Sleep. Adequate sleep (7-9 hours) supports nocturnal testosterone secretion. Chronic short sleep can drop testosterone 10-15% in healthy young men within a week. See our sleep and myostatin article.

Body fat. Excess adipose tissue (particularly visceral fat) raises aromatase activity, which converts testosterone to estradiol. The net result is lower free testosterone and higher estrogen. Both directions worsen the myostatin axis.

Training. Resistance training raises testosterone acutely (small, brief spike) and supports chronic testosterone maintenance through downstream metabolic and inflammatory effects. Sedentary adults run lower testosterone than active peers of the same age and body fat.

These factors stack. A 50-year-old man with 28% body fat sleeping 5 hours and not training is running lower testosterone, higher myostatin, and worse muscle protein turnover than the same person sleeping 8 hours, training 3x per week, and at 18% body fat. The intervention is the lifestyle factors, not a prescription.

A few popular claims worth flagging.

Test boosters from supplement stores. Tribulus, fenugreek, D-aspartic acid, and others have weak to no human evidence for meaningful testosterone elevation in healthy men, and consequently no documented myostatin-axis effect.

Generic "hormone optimizing" clinics with high-dose TRT for non-hypogonadal men. This is not therapeutic testosterone replacement; it is supraphysiological dosing with associated risks. The myostatin literature on this is sparse and the cardiovascular and endocrine downsides are well documented.

Topical testosterone gels marketed direct-to-consumer. Often produce inconsistent serum testosterone responses depending on application and absorption. Legitimate TRT is monitored with periodic labs and dose adjustments — DTC gels without monitoring are not the same product clinically.

Sources

Frequently Asked Questions

Does testosterone lower myostatin?

Yes, at the muscle tissue level. The cleanest human data comes from a 2019 JCEM study in hypogonadal men on standard TRT (250 mg every 2 weeks for 22 weeks): muscle myostatin expression dropped 29%, FGF2 rose 134%, and IGF-1 rose 31%. Serum myostatin was unchanged — the action is intramuscular, not in circulating blood.

Will TRT make my training more productive?

In genuinely hypogonadal men, yes. TRT reliably increases lean mass, decreases fat mass, raises strength, and improves training response, and a meaningful part of that happens through the myostatin-FGF2-IGF-1 axis described in the JCEM paper. In men with already-normal testosterone, supplemental testosterone is not therapeutically indicated and adding it crosses from medicine into performance enhancement, with the associated risks.

Do natural testosterone boosters lower myostatin?

Almost certainly not in any meaningful way. Most test boosters (tribulus, D-aspartic acid, fenugreek) have weak or null effects on testosterone in healthy adults in controlled studies. With no reliable testosterone elevation, there is no expected myostatin-axis effect. The lifestyle interventions (sleep, training, body composition, micronutrient sufficiency) are where natural testosterone support actually lives.

Will my serum myostatin drop if I start TRT?

Maybe not, even though your muscle myostatin will. The Dhindsa study showed muscle expression dropping 29% with no change in serum myostatin. This is part of why commercial blood myostatin testing is a poor proxy for your training and hormonal status — the local muscle environment can change meaningfully without the blood number moving.

What about women and myostatin?

The testosterone-myostatin link is preserved at the lower hormonal levels women have. Women's smaller endogenous testosterone pool still suppresses muscle myostatin, and aging-related testosterone decline in women contributes to perimenopausal muscle changes the same way it does in men. See our myostatin in women article for the full picture.

Does YK-11 actually inhibit myostatin?

The marketing claim is much stronger than the evidence. YK-11 is a synthetic steroidal SARM with androgen receptor activity. The "myostatin inhibitor" framing comes from in-vitro work showing it raised follistatin expression in cultured muscle cells, but the translation to human myostatin suppression is unsupported. See our YK-11 article for the full breakdown.

This article is for educational purposes only and is not medical advice. Testosterone replacement therapy requires formal diagnosis of hypogonadism, monitoring with periodic labs, and prescription by a qualified physician (typically endocrinology, urology, or primary care with TRT expertise). Self-administration of testosterone, use of supraphysiological doses, or use of SARMs without medical supervision carries cardiovascular, endocrine, and legal risks. Do not start testosterone or SARMs based on online information.